Literature DB >> 15888735

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC).

V V Kataja1, M Colleoni, J Bergh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888735     DOI: 10.1093/annonc/mdi816

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

Review 1.  Lapatinib.

Authors:  Sohita Dhillon; Antona J Wagstaff
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.

Authors:  Fabrice Andre; Kristine Broglio; Lajos Pusztai; Narjiss Berrada; John R Mackey; Jean Marc Nabholtz; Stephen Chan; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2010-04-26

3.  Controversies on the management of clinical situations with low therapeutic effectiveness in oncology.

Authors:  José Expósito; Juan José Bretón; Carmen Domínguez; Joana Pons
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

Review 4.  Endocrine therapy of metastatic breast cancer.

Authors:  Laura Rodríguez Lajusticia; Miguel Martín Jiménez; Sara López-Tarruella Cobo
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

5.  Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.

Authors:  Hye Jin Kim; Jin-Soo Kim; Myung-Deok Seo; So-Yeon Oh; Do-Youn Oh; Jee Hyun Kim; Se-Hoon Lee; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  Cancer Res Treat       Date:  2008-06-30       Impact factor: 4.679

6.  Intravascular large B-cell lymphoma diagnosed on prostate biopsy: a case report.

Authors:  Nazan Özsan; Banu Sarsık; Asu Fergün Yılmaz; Adnan Şimşir; Ayhan Dönmez
Journal:  Turk J Haematol       Date:  2014-12-05       Impact factor: 1.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.